PandemieGrippaleV1, PubMed, Corpus, bibRecord, 000153

Antiviral Therapy for the Next Influenza Pandemic.

Identifieur interne : 000153 ( PubMed/Corpus ); précédent : 000152; suivant : 000154

Antiviral Therapy for the Next Influenza Pandemic.

Source :

Tropical medicine and infectious disease [ 2414-6366 ] ; 2019.

RBID : pubmed:31003518

Abstract

Influenza antivirals will play a critical role in the treatment of outpatients and hospitalised patients in the next pandemic. In the past decade, a number of new influenza antivirals have been licensed for seasonal influenza, which can now be considered for inclusion into antiviral stockpiles held by the World Health Organization (WHO) and individual countries. However, data gaps remain regarding the effectiveness of new and existing antivirals in severely ill patients, and regarding which monotherapy or combinations of antivirals may yield the greatest improvement in outcomes. Regardless of the drug being used, influenza antivirals are most effective when treatment is initiated early in the course of infection, and therefore in a pandemic, effective strategies which enable rapid diagnosis and prompt delivery will yield the greatest benefits.

DOI: 10.3390/tropicalmed4020067
PubMed: 31003518

Links to Exploration step

pubmed:31003518

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Antiviral Therapy for the Next Influenza Pandemic.</title>
<author><name sortKey="Hurt, Aeron C" sort="Hurt, Aeron C" uniqKey="Hurt A" first="Aeron C" last="Hurt">Aeron C. Hurt</name>
<affiliation><nlm:affiliation>WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. Aeron.Hurt@influenzacentre.org.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2019">2019</date>
<idno type="RBID">pubmed:31003518</idno>
<idno type="pmid">31003518</idno>
<idno type="doi">10.3390/tropicalmed4020067</idno>
<idno type="wicri:Area/PubMed/Corpus">000153</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000153</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Antiviral Therapy for the Next Influenza Pandemic.</title>
<author><name sortKey="Hurt, Aeron C" sort="Hurt, Aeron C" uniqKey="Hurt A" first="Aeron C" last="Hurt">Aeron C. Hurt</name>
<affiliation><nlm:affiliation>WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. Aeron.Hurt@influenzacentre.org.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Tropical medicine and infectious disease</title>
<idno type="eISSN">2414-6366</idno>
<imprint><date when="2019" type="published">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Influenza antivirals will play a critical role in the treatment of outpatients and hospitalised patients in the next pandemic. In the past decade, a number of new influenza antivirals have been licensed for seasonal influenza, which can now be considered for inclusion into antiviral stockpiles held by the World Health Organization (WHO) and individual countries. However, data gaps remain regarding the effectiveness of new and existing antivirals in severely ill patients, and regarding which monotherapy or combinations of antivirals may yield the greatest improvement in outcomes. Regardless of the drug being used, influenza antivirals are most effective when treatment is initiated early in the course of infection, and therefore in a pandemic, effective strategies which enable rapid diagnosis and prompt delivery will yield the greatest benefits.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31003518</PMID>
<DateRevised><Year>2020</Year>
<Month>02</Month>
<Day>25</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2414-6366</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>4</Volume>
<Issue>2</Issue>
<PubDate><Year>2019</Year>
<Month>Apr</Month>
<Day>18</Day>
</PubDate>
</JournalIssue>
<Title>Tropical medicine and infectious disease</Title>
<ISOAbbreviation>Trop Med Infect Dis</ISOAbbreviation>
</Journal>
<ArticleTitle>Antiviral Therapy for the Next Influenza Pandemic.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">E67</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.3390/tropicalmed4020067</ELocationID>
<Abstract><AbstractText>Influenza antivirals will play a critical role in the treatment of outpatients and hospitalised patients in the next pandemic. In the past decade, a number of new influenza antivirals have been licensed for seasonal influenza, which can now be considered for inclusion into antiviral stockpiles held by the World Health Organization (WHO) and individual countries. However, data gaps remain regarding the effectiveness of new and existing antivirals in severely ill patients, and regarding which monotherapy or combinations of antivirals may yield the greatest improvement in outcomes. Regardless of the drug being used, influenza antivirals are most effective when treatment is initiated early in the course of infection, and therefore in a pandemic, effective strategies which enable rapid diagnosis and prompt delivery will yield the greatest benefits.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hurt</LastName>
<ForeName>Aeron C</ForeName>
<Initials>AC</Initials>
<Identifier Source="ORCID">0000-0003-1826-4314</Identifier>
<AffiliationInfo><Affiliation>WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia. Aeron.Hurt@influenzacentre.org.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Microbiology and Immunology, University of Melbourne, Parkville, VIC 3010, Australia. Aeron.Hurt@influenzacentre.org.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2019</Year>
<Month>04</Month>
<Day>18</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Trop Med Infect Dis</MedlineTA>
<NlmUniqueID>101709042</NlmUniqueID>
<ISSNLinking>2414-6366</ISSNLinking>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antivirals</Keyword>
<Keyword MajorTopicYN="N">influenza</Keyword>
<Keyword MajorTopicYN="N">pandemic</Keyword>
<Keyword MajorTopicYN="N">stockpile</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year>
<Month>02</Month>
<Day>28</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2019</Year>
<Month>04</Month>
<Day>02</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2019</Year>
<Month>04</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2019</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2019</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2019</Year>
<Month>4</Month>
<Day>21</Day>
<Hour>6</Hour>
<Minute>1</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">31003518</ArticleId>
<ArticleId IdType="pii">tropicalmed4020067</ArticleId>
<ArticleId IdType="doi">10.3390/tropicalmed4020067</ArticleId>
<ArticleId IdType="pmc">PMC6630704</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Curr Top Microbiol Immunol. 1992;176:119-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1600749</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2005 Oct 1;366(9492):1175-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16198766</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2006 Oct 17;145(8):599-609</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16940336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2008 Jan 17;358(3):261-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18199865</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2009 Oct 24;374(9699):1417; author reply 1417-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19854362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2010 Jun 10;362(23):2166-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20558367</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2010 Oct 15;202(8):1154-60</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20831384</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect. 2011 Oct;63(4):288-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21722665</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Obstet Gynaecol Res. 2012 May;38(5):757-62</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22487092</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 2012 Oct 1;90(10):782-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23109746</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2013 Nov;7 Suppl 3:72-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24215385</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2014 Apr 09;348:g2545</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24811411</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2014 May;2(5):395-404</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24815805</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2015 May 2;385(9979):1729-1737</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25640810</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2016 Feb 15;213(4):574-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26374911</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMC Infect Dis. 2016 Oct 10;16(1):552</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27724915</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Influenza Other Respir Viruses. 2017 May;11(3):240-246</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28146320</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2017 May 15;64(10):1328-1334</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28199524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2018 Sep 6;379(10):913-923</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30184455</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trop Med Infect Dis. 2018 Feb 02;3(1):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30274415</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Infect Dis. 2019 Apr;32(2):176-186</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30724789</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Euro Surveill. 2019 Mar;24(12):null</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30914078</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EMBO J. 1985 Nov;4(11):3021-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4065098</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/PandemieGrippaleV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000153 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000153 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    PandemieGrippaleV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:31003518
   |texte=   Antiviral Therapy for the Next Influenza Pandemic.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:31003518" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a PandemieGrippaleV1

This area was generated with Dilib version V0.6.34.
Data generation: Wed Jun 10 11:04:28 2020. Site generation: Sun Mar 28 09:10:28 2021

	Serveur d'exploration sur les pandémies grippales
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les pandémies grippales

Antiviral Therapy for the Next Influenza Pandemic.

Antiviral Therapy for the Next Influenza Pandemic.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki